
Guardant Health's Shield Mutlicancer Detection Blood Test Granted FDA Breakthrough Device Designation
Guardant Health announced June 2 that the FDA has granted Breakthrough Device designation to the company's Shield multi-cancer detection (MCD) test, advancing the potential for a single, blood-based screening tool for multiple solid tumor types to be …